ScreenerHero

SER Serina Therapeutics, Inc.

AMEX · US · Healthcare · Biotechnology · serinatherapeutics.com
2.010USD-1.47%Mkt Cap: 51.05M $P/E: —

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap51.05M USD
Enterprise Value32.55M USD
Revenue (TTM)0 USD
Gross Profit-14.07M USD
Net Income (TTM)-19.18M USD
Revenue/Share0.00 USD
Last Price2.010 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees16
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.94
PEG—
EV/EBITDA-1.27
EV/Revenue—
P/SInfinity
P/B2.77
EPS (TTM)-1.87
EPS (Forward)-1.05
52W Range
1.22017% of range5.830
52W High5.830 USD
52W Low1.220 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE51843.24%
ROA-275.96%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-17.95M USD
CapEx (TTM)59.00K USD
FCF Margin—
FCF Yield-24.19%
Net Debt-19.27M USD
Net Debt/EBITDA0.75
Balance Sheet
Debt/Equity-84.92
Current Ratio6.65
Quick Ratio6.12
Book Value/Sh0.74 USD
Cash/Share0.91 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split28:1000
Split DateMar 15, 2024
Analyst Consensus
Rating—
Target (Mean)9.500 USD
Upside (mean)+372.6%
Target Range8.000 USD – 11.00 USD
8.000+372.6% to mean11.00
# Analysts2
Ownership
Shares Out.25.40M
Float11.15M
Insiders50.76%
Institutions5.55%
Short Interest
Short Ratio1.8d
Short % Float0.54%
Short % Out.0.47%
Shares Short119.36K
Short (prev mo.)145.55K
Technical
SMA 502.386 (-15.8%)
SMA 2002.149 (-6.5%)
Beta0.16
S&P 52W Chg16.45%
Avg Vol (30d)86.00K
Avg Vol (10d)126.70K
Technical Indicators
RSI (14)38.8
MACD-0.1177
MACD Signal-0.1000
MACD Hist.-0.0178
BB Upper2.583 USD
BB Middle2.191 USD
BB Lower1.799 USD
BB Width35.80%
ATR (14)0.1646 USD
Vol Ratio (20d)0.12x